Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer

Inclusion Criteria: 1. Patients aged \>= 20 years at informed consent. 2. Patients who have provided written informed consent themselves. 3. Patients who have metastatic and/or advanced lesion 4. Documentation of ER-positive and/or PR-positive tumor (\>=1% positive stained cells). 5. Patients with cancer confirmed to be HER2-negative. 6. Patients with confirmed menopause 7. Patients who have plans of 2nd hormone therapy. 8. Patients with a measurable lesion based on RECIST 1.1 9. Patients with ECOG PS of 0 to 1. 10. Patients without any severe disorder in the major organs. Exclusion Criteria: \- Exclusion Criteria: 1. Active or prior documented autoimmune disease within the past 2 years. 2. Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab 3. Patients with central nervous system metastasis 4. Patients with life-threatening disease. 5. Patients with a history of treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 or anti-CTLA-4 antibody drug. 6. Patients who have received live vaccination within 30 days before start of the investigational products. 7. Patients with a past medical history of pneumonia requiring steroid treatment or with a past medical history of interstitial pneumonia. 8. Patients considered ineligible for participation in this study by their attending physicians.